Search
Vericel Corp
VCELAdd to Watchlist
40.100USD
+0.970+2.48%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
2.05BMarket Cap
93.39P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Vericel Corp is 8.50, ranking 34 out of 157 in the Pharmaceuticals industry. The average price target is 55.00, with a high of 62.00 and a low of 50.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
55.429
Target Price
+38.23%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Vericel Corp
VCEL
8
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Vericel Corp's expected revenue for the next quarter?
Vericel Corp's expected revenue is 72.69M.
What is Vericel Corp's price target?
Analysts forecast that Vericel Corp's price target is USD 55.00, with the highest forecast at USD 62.00 and the lowest forecast at USD 50.00.
How have Vericel CorpVCEL's recent earnings per share performed?
The market expectation was USD -0.12, while Vericel CorpVCEL's earnings per share (EPS) for the previous quarter was USD 0.46. EPS for the next quarter is expected at USD -0.03.
What is the analyst rating for Vericel Corp?
Based on the ratings of Vericel Corp's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
